Next Article in Journal
Krüppel-like Factor-9 and Krüppel-like Factor-13: Highly Related, Multi-Functional, Transcriptional Repressors and Activators of Oncogenesis
Next Article in Special Issue
Intralesional Treatments for Invasive Cutaneous Squamous Cell Carcinoma
Previous Article in Journal
Prediction of Neoadjuvant Chemoradiotherapy Response in Rectal Cancer Patients Using Harmonized Radiomics of Multcenter 18F-FDG-PET Image
Previous Article in Special Issue
Topical and Intralesional Immunotherapy for the Management of Skin Cancer in Special Locations: Lips and Eyelids
Systematic Review
Peer-Review Record

Topical Imiquimod in Primary Cutaneous Extramammary Paget’s Disease: A Systematic Review

Cancers 2023, 15(23), 5665;
by Fátima Mayo-Martínez 1,*, Ruggero Moro 2,3, David Millán-Esteban 1,2, Elisa Ríos-Viñuela 2, Iker Javier Bautista 4,5, Eduardo Nagore 1, Onofre Sanmartín 1 and Beatriz Llombart 1,*
Reviewer 1:
Reviewer 2: Anonymous
Cancers 2023, 15(23), 5665;
Submission received: 10 November 2023 / Revised: 23 November 2023 / Accepted: 28 November 2023 / Published: 30 November 2023
(This article belongs to the Special Issue Topical and Intralesional Immunotherapy for Skin Cancer)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

Thanks a lot for allowing me to review this interesting paper. Vular Paget disease is a quite rare condition were surgical management often fails. For this reason the need for medical treatment is high.

The author review the literature on this topic but it should be accurately  stressed that some studies report on results also on other site of disease outside the vulva and this may be a bias.

Moreover in many cases the schedule of the treatment was different.

Despite this limitations the paper covers a very intereesting topic and is worthy to be published. 

Comments on the Quality of English Language

Good paper on a rare but interesting topic. Worthy to be published.

Author Response

Thank you for your kind comment. Indeed, most of the publications of extrammamary Paget’s disease focus on vulvar Paget's disease, while this systematic review included extrammamary Paget’s disease localized in any anatomical area.

Reviewer 2 Report

Comments and Suggestions for Authors

Dear authors,

thank you for the interesting paper. I hope this will help to shed some light on an emerging treatment of a rare disease. The study design is appropriate and includes all the relevant studies on the topic. However some issues must be addressed before considering it for publication.


- as for the introduction, a recent multi society statement has been issued by a board of expert, recommending the use of imiquimod in vulvar Paget disease. I think it should be worth citing: 10.1136/ijgc-2021-003262

- line 64: correct "immunotherapy"

- line 71 onward: I think you should provide updated references upon that. I see that a recent review article on Imiquimod has been published, you should consider citing it: 10.1002/jmv.29238

- line 79: you should add reference 50 (10.1016/j.suronc.2021.101581) to this statement (as you later stated in line 355)

- line 217: correct "the majority.."

- line 325-326: I prefer to refer to non-preatreated EMPD as "naive EMPD"

- line 337 onward: uptake references for Imiquimod activity (10.1002/jmv.29238)

Thank you for your precious work


Comments on the Quality of English Language

Minor editing

Author Response

Thank you for your review and your suggestions. We add the interesting publications that you recommended. We have also made the suggested orthographic corrections.

Round 2

Reviewer 2 Report

Comments and Suggestions for Authors

Dear authors,

thank for your precious work. The manuscript has been well improved and deserves publication.


Back to TopTop